All In Biotech

Drug Trial Radar · NCT03642288

The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction

The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction:A Retrospective Study

Last checked: Nov 19, 2026Latest source record: Aug 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

112

Actual

Start

Apr 1, 2014

Primary completion

Jun 30, 2018

Study completion Dec 31, 2018

Sponsor

Lead sponsor
Jinling Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic radiation enteropathy (CRE) is a major issue for long-term cancer survivors. The aim of this study was to clarify the diagnostic and therapeutic effect of the Gastrografin (GG) challenge for patients with CRE induced small bowel obstruction SBO.

Conditions

  • CRE-induced SBO

Interventions

  • GastrografinDrug

    Patients with CRE-induced SBO or ASBO both received GG challenge.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of successful conservative treatmentTime frame: 5 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.